Sandbox:Qurrat: Difference between revisions

Jump to navigation Jump to search
Line 10: Line 10:
| colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Clinical manifestations</small>'''
| colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Clinical manifestations</small>'''
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Para-clinical findings</small>
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Para-clinical findings</small>
|
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Gold standard</small>'''
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Gold standard</small>'''
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Additional findings</small>
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Additional findings</small>
Line 16: Line 15:
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Symptoms</small>'''
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Symptoms</small>'''
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Physical examination</small>
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Physical examination</small>
|
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Lab Findings</small>
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Lab Findings</small>
Line 67: Line 65:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Uterine sarcoma|<small>Uterine</small>]]  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Uterine sarcoma|<small>Uterine</small>]]  
Line 86: Line 84:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphoma|<small>Uterine</small>]]  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphoma|<small>Uterine</small>]]  
Line 105: Line 103:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>Uterine</small> <small>[[leiomyoma]]</small>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>Uterine</small> <small>[[leiomyoma]]</small>
Line 123: Line 121:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>Malignant</small> <small>mixed</small>  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>Malignant</small> <small>mixed</small>  
Line 149: Line 147:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Cervical cancer|Cervical]]</small> <small>[[Cervical cancer|cancer]]</small>  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Cervical cancer|Cervical]]</small> <small>[[Cervical cancer|cancer]]</small>  
Line 173: Line 171:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Metastasis]]</small> <small>to the uterus</small>  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Metastasis]]</small> <small>to the uterus</small>  
Line 195: Line 193:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial polyp|<small>Endometrial</small>]]  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial polyp|<small>Endometrial</small>]]  
Line 214: Line 212:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial hyperplasia|<small>Endometrial</small>]]  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial hyperplasia|<small>Endometrial</small>]]  
Line 233: Line 231:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Fetus]]</small>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Fetus]]</small>
Line 251: Line 249:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adenomyoma|<small>Uterine</small>]]  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adenomyoma|<small>Uterine</small>]]  
Line 271: Line 269:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hematometra|<small>Hematometra</small>]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hematometra|<small>Hematometra</small>]]
Line 289: Line 287:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|-
|-
|
|

Revision as of 18:49, 29 January 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

tab

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Vaginal

bleeding

Pelvic

pain

pelvic

pressures

Abdominal

distentions

Pelvic

mass

Abdominal

distension

Physical exam 3 Hb CEA-19 Pelvic

examination

Pelvic

ultrasound

MRI
Uterine cancer
Uterine

sarcoma

Uterine

lymphoma

Uterine leiomyoma
Malignant mixed

Mullerian

tumour

(MMMT)

of the uterus

Cervical cancer

with

uterine

invasion

Metastasis to the uterus

from a non gynaecologcial

malignancy

Endometrial

polyp

Endometrial

hyperplasia

Fetus
Uterine

adenomyoma

Hematometra
Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Symptom 1 Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Lab 1 Lab 2 Lab 3 Imaging 1 Imaging 2 Imaging 3
Uterine cancer
Uterine sarcoma
Infection
Diseases Symptom 1 Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Lab 1 Lab 2 Lab 3 Imaging 1 Imaging 2 Imaging 3 Histopathology Gold standard Additional findings
Abscess
Septic emboli
Fungi
Differential Diagnosis 1
Differential Diagnosis 2
Differential Diagnosis 3
Diseases Symptom 1 Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Lab 1 Lab 2 Lab 3 Imaging 1 Imaging 2 Imaging 3 Histopathology Gold standard Additional findings
Differential Diagnosis 4
Differential Diagnosis 5
Differential Diagnosis 6

Table for Differential Diagnosis of Small Intestine Cancer

ABBREVIATIONS:

N/A: Not available, NL: Normal,

References